Global Ganja Report

In a Capitol Hill hearing that advocates hailed as “historic,” numerous Congress members openly embraced lifting the federal strictures on cannabis—and even outright legalization. The discussion was particularly framed in terms of recognizing and correcting the racial and social iniquities of cannabis prohibition and the "war on drugs."

The Cannabis Cultural Association won at least a limited legal victory, with a federal appeals court ruling that the DEA must consider with "alacrity" their petition to have cannabis rescheduled.

A new report by the British think-tank Prohibition Partners foresees a $5.8 billion cannabis market in Asia by 2024—if the tentative seeds of liberalization now witnessed across the continent in fact bear fruit.

There is a growing consensus among hemp advocates that the 0.3% limit for THC content is arbitrary and is holding back the industry. And the man widely credited with arriving at this limit himself agrees.

The Contested Border
"It seems like it is pretty much pulled out of air. We ought to be looking to science to determine an appropriate threshold, determine the level at which cannabis is psychoactive and make that the standard."

This typical view is offered by attorney Patrick Goggin of Hoban Law Group, the international firm specializing in cannabis. Goggin is one of the industry's legal heavy-hitters, and has particular experience in the question of the contested border between hemp and marijuana.

FDA commissioner Scott Gottlieb has suddenly announced that he is stepping down, leaving lots of unfinished business—including the status of CBD under the agency's regs. Biotech stocks are taking a tumble on the news, while tobacco is bullish and cannabis is mixed.

A newly released study from the University of New Mexico actually finds more therapeutic benefits to THC than its sexy sibling cannabinoid CBD. However, the study is based on a single cellphone app—which, for better or worse, is certainly unorthodox methodology.

The World Health Organization has released its long-anticipated recommendation on cannabis scheduling. But rather than removing it from Schedule I of the Single Convention, it only removes it from Schedule IV, where it is also listed. CBD, however, has indeed been de-scheduled entirely.

A House bill to legalize cannabis, removing it from the Controlled Substances Act and treating it like alcohol, is wryly dubbed HR 420. It isn't the first such bill in Congress—but with the recent change in House leadership, this time it may actually stand a chance of passing.